Autophagy Agonists

Cat.No.	Product Name	Information	Product Use Citations
S8597	LYN-1604	LYN-1604 is a potential ULK1 agonist with IC50 of 1.66 μM against MDA-MB-231 cells and it binds to wild-type ULK1 with a binding affinity in the nanomole range (Kd=291.4 nM). The ULK1 (Y89A) mutant protein caused a sharp decrease in binding affinity with lower response and Kd than wild-type ULK1, ULK1 (K50A) and ULK1 (L53A) mutants.	Journal of Virology, January 26, 2022, e0155021 bioRxiv, April 15, 2024, nan Journal of Mens Health, 2025, 37-44
S6756	Siramesine HCl	Siramesine (Lu 28-179) is a sigma receptor agonist, selective for the σ2 subtype with IC50 values of 0.12 nM and 17 nM for σ2 and σ1 receptors respectively.	Journal of Translational Medicine, 2025, 780 J Transl Med, 2025, 23(1):780
E5898^New	SKLB-D18	SKLB-D18 is a first-in-class, potent, and selective inhibitor of ERK1/2 and ERK5 with an IC50's of 38.69 nM, 40.12 nM, and 59.72 nM, respectively, that also acts as an agonist of autophagy. It modulates mTOR/p70S6K and NCOA4-mediated ferroptosis, showing strong anti-tumor activity and offering a promising monotherapy strategy to overcome resistance in ERK1/2-targeted therapy for triple-negative breast cancer (TNBC).

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S8597

LYN-1604

LYN-1604 is a potential ULK1 agonist with IC50 of 1.66 μM against MDA-MB-231 cells and it binds to wild-type ULK1 with a binding affinity in the nanomole range (Kd=291.4 nM). The ULK1 (Y89A) mutant protein caused a sharp decrease in binding affinity with lower response and Kd than wild-type ULK1, ULK1 (K50A) and ULK1 (L53A) mutants.

Journal of Virology, January 26, 2022, e0155021

bioRxiv, April 15, 2024, nan

Journal of Mens Health, 2025, 37-44

S6756

Siramesine HCl

Siramesine (Lu 28-179) is a sigma receptor agonist, selective for the σ2 subtype with IC50 values of 0.12 nM and 17 nM for σ2 and σ1 receptors respectively.

Journal of Translational Medicine, 2025, 780

J Transl Med, 2025, 23(1):780

E5898^New

SKLB-D18

SKLB-D18 is a first-in-class, potent, and selective inhibitor of ERK1/2 and ERK5 with an IC50's of 38.69 nM, 40.12 nM, and 59.72 nM, respectively, that also acts as an agonist of autophagy. It modulates mTOR/p70S6K and NCOA4-mediated ferroptosis, showing strong anti-tumor activity and offering a promising monotherapy strategy to overcome resistance in ERK1/2-targeted therapy for triple-negative breast cancer (TNBC).